

**Supplementary Table 2.** Summary of rSBA immunogenicity results (rSBA full analysis set)

	No.	Participants with titers (%)		GMT (95% CI)	GMR <sup>a</sup> (95% CI)
		≥8 (95% CI)	≥128 (95% CI)		
<b>MenA</b>					
1M post-vac	115	100 (96.8 to 100.0)	100 (96.8 to 100.0)	7,394.2 (6,057.4 to 9,025.9)	0.32 (0.25 to 0.40)
1Y post-vac	108	99 (94.9 to >99.9)	98 (93.5 to 99.8)	2,269.5 (1,761.1 to 2,924.6)	
<b>MenC</b>					
1M post-vac	115	99 (95.3 to >99.9)	92 (85.7 to 96.4)	735.1 (545.2 to 991.0)	0.019 (0.013 to 0.027)
1Y post-vac	108	54 (43.8 to 63.3)	30 (21.2 to 39.2)	17.2 (11.3 to 26.1)	
<b>MenW</b>					
1M post-vac	115	100 (96.8 to 100.0)	98 (93.9 to 99.8)	2,718.7 (2,031.8 to 3,637.9)	0.039 (0.025 to 0.059)
1Y post-vac	108	69 (59.8 to 77.9)	62 (52.2 to 71.2)	114.0 (65.2 to 199.4)	
<b>MenY</b>					
1M post-vac	116	100 (96.9 to 100.0)	98 (93.9 to 99.8)	2,226.7 (1,731.2 to 2,864.0)	0.13 (0.096 to 0.18)
1Y post-vac	107	90 (82.3 to 94.8)	80 (71.6 to 87.4)	310.9 (203.2 to 475.7)	

rSBA, serum bactericidal assay using rabbit serum; CI, confidence interval; GMT, geometric mean titer; GMR, geometric mean ratio; M, month; post-vac, post-vaccination with four MenACWY-CRM doses; Y, year.

<sup>a</sup>One-year vs. 1-month post-vaccination GMT ratio.